Drug intelligence / Profile preview

eribulin + ramucirumab

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of eribulin, a non-taxane synthetic microtubule inhibitor, and ramucirumab, a human IgG1 monoclonal antibody targeting VEGFR-2. Eribulin inhibits microtubule polymerization without affecting depolymerization, causing apoptosis through mitotic block at G2-M phase. It also alters the tumor microenvironment, exhibits anti-angiogenic properties, and decreases migration and invasiveness. Ramucirumab binds to VEGFR-2, preventing binding of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D), thereby inhibiting endothelial cell proliferation, permeability, and migration.

Brand names: Cyramza (ramucirumab)Halaven (eribulin)

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on eribulin + ramucirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eribulin + ramucirumab.